Abstract: Disclosed in the present invention are a pharmaceutical composition, a preparation, and a preparation method therefor and the use thereof. The pharmaceutical composition contains an active ingredient and a pharmaceutically acceptable excipient. The active ingredient contains a compound represented by formula A. The compound represented by formula A is selected from one, two or more of the crystal form I, the crystal form III and the crystal form V. The excipient is selected-from or comprises, but is not limited to, one, two or more of the following excipients: a diluent, a disintegrant, an adhesive, a glidant and a lubricant. The pharmaceutical composition and the preparation of the present invention have a good safety and/or stability, and a high P2X3 antagonistic activity, and have less effect on the taste.

Abstract: An acid addition salt of a ROCK inhibitor, and a crystal form, a composition and the pharmaceutical use thereof are provided. The acid addition salt is an acid addition salt of compound A and any one of the following acids: hydrochloric acid, p-toluenesulfonic acid, benzenesulfonic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, sulfuric acid, methanesulfonic acid, phosphoric acid, succinic acid or citric acid (A). The acid addition salt of compound A and the crystal form thereof have the characteristics of high solubility, good stability, high purity, few impurities and high bioequivalence, and are beneficial for the storage, quality control and druggability of drugs.

Abstract: Provided are a crystalline form of a compound represented by formula A, the crystalline form being crystalline form I, crystalline form II, crystalline form III, crystalline form IV, crystalline form V, crystalline form VI, crystalline form VII, crystalline form VIII or crystalline form IX, a preparation method therefor, a composition thereof, and an application thereof in the preparation of a P2X3 receptor antagonist or an application thereof in the preparation of drugs preventing and/or treating pains, urinary tract illness or respiratory system illness. The compound has high P2X3 antagonist activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.